Hepatitis C virus- Biology, host evasion strategies, and promising new therapies on the horizon

被引:34
|
作者
Qureshi, Sohail A. [1 ]
机构
[1] Aga Khan Univ Hosp, Dept Biol & Biomed Sci, Karachi 74800, Pakistan
关键词
hepatitis C; hepatitis C virus (HCV); antiviral therapy; signaling pathways; evasion strategies;
D O I
10.1002/med.20063
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Hepatitis C reduces the quality of life for some 170 million people around the globe and is one of the most prevalent diseases on the planet. It is caused by the hepatitis C virus (HCV) that is replicated by an error-prone polymerase and therefore undergoes rapid evolution. To date, although much has been learned about the biology of HCV, only a partially effective combination therapy comprised of ribavirin and pegylated-interferon-alpha is available to hepatitis C sufferers. Given the prevalence of hepatitis C, together with the fact that almost half the chronically infected HCV patients are refractory to current therapy, there is an urgent need for an efficacious immuno-prophylactic that protects individuals from HCV infection, as well as drugs that impede the viral life cycle effectively and eradicate infection. Herein, I provide an overview of the molecular biology of HCV, highlighting the functions of different virally encoded proteins in terms of how they alter signaling pathways of host cell to establish an infection and discuss whether a more promising therapy for treating hepatitis C is anywhere in sight. (c) 2006 Wiley Periodicals, Inc.
引用
收藏
页码:353 / 373
页数:21
相关论文
共 50 条
  • [41] New insights into the molecular and cellular biology of hepatitis C virus
    Konan, Kouacou V.
    FASEB JOURNAL, 2007, 21 (05): : A148 - A148
  • [42] Emerging therapies for hepatitis C virus
    Birerdinc, Aybike
    Younossi, Zobair M.
    EXPERT OPINION ON EMERGING DRUGS, 2010, 15 (04) : 535 - 544
  • [43] Gene Therapies for Hepatitis C Virus
    Verstegen, Monique M. A.
    Pan, Qiuwei
    van der Laan, Luc J. W.
    GENE THERAPY FOR HIV AND CHRONIC INFECTIONS, 2015, 848 : 1 - 29
  • [44] Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma
    Kim, W
    Lim, SO
    Kim, JS
    Ryu, YH
    Byeon, JY
    Kim, HJ
    Kim, YI
    Heo, JS
    Park, YM
    Jung, GH
    CLINICAL CANCER RESEARCH, 2003, 9 (15) : 5493 - 5500
  • [45] An Inactivated Hepatitis C Virus Vaccine on the Horizon?
    Houghton, Michael
    Law, John Lokman
    Tyrrell, D. Lorne
    GASTROENTEROLOGY, 2013, 145 (02) : 285 - 288
  • [46] Mass spectrometry for genotyping hepatitis C virus: A promising new approach
    Cook, L
    Jerome, KR
    CLINICAL CHEMISTRY, 2005, 51 (07) : 1091 - 1092
  • [47] Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma
    Lee, Chun-Feng
    Ling, Zhi-Qiang
    Zhao, Ting
    Lee, Kuan-Rong
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (39) : 6072 - 6077
  • [48] New therapies for hepatitis C
    Gil-Guerrero, Luca
    Sarobe, Pablo
    Prieto, Jesus
    MEDICINA CLINICA, 2006, 127 (03): : 104 - 112
  • [49] New therapies for hepatitis C
    Modi, Apurva A.
    Hoofnagle, Jay H.
    HEPATOLOGY, 2007, 46 (03) : 615 - 617
  • [50] New Hepatitis C Therapies
    Pawlotsky, Jean-Michel
    SEMINARS IN LIVER DISEASE, 2014, 34 (01) : 7 - 8